RXMD — Progressive Care Income Statement
0.000.00%
Last trade - 00:00
- $11.95m
- $5.33m
- $49.73m
- 61
- 51
- 14
- 37
2019 December 31st | C2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 32.6 | 38.9 | 38.9 | 40.6 | 49.7 |
Cost of Revenue | |||||
Gross Profit | 7.97 | 8.96 | 10.2 | 9.7 | 15.2 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 33.6 | 39.5 | 39 | 42.8 | 69 |
Operating Profit | -0.935 | -0.554 | -0.19 | -2.15 | -19.2 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -2.5 | -1.44 | 0.218 | -5.9 | -19.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | -2.51 | -1.45 | 0.218 | -5.9 | -19.4 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -2.51 | -1.45 | 0.218 | -5.9 | -19.4 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -2.51 | -1.45 | 0.218 | -6.45 | -19.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.16 | -0.794 | -0.265 | -2.31 | -0.051 |